Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
LSE - Delayed Quote GBp

Allergy Therapeutics plc (AGY.L)

Compare
6.80
+0.14
+(2.10%)
At close: February 21 at 4:35:20 PM GMT
Currency in GBP All numbers in thousands
Download
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
55,199
55,199
59,587
72,768
84,331
Cost of Revenue
25,462
25,462
26,342
23,262
22,106
Gross Profit
29,737
29,737
33,245
49,506
62,225
Operating Expense
63,755
63,755
68,149
61,751
58,194
Operating Income
-34,018
-34,018
-34,904
-12,245
4,031
Net Non Operating Interest Income Expense
-3,909
-3,909
-2,112
-412
-374
Pretax Income
-39,166
-39,166
-41,766
-12,657
3,657
Tax Provision
1,050
1,050
1,305
1,119
771
Net Income Common Stockholders
-40,216
-40,216
-43,071
-13,776
2,886
Diluted NI Available to Com Stockholders
-40,216
-40,216
-43,071
-13,776
2,886
Basic EPS
-0.01
--
-0.08
-0.02
0.00
Diluted EPS
-0.01
--
-0.08
-0.02
0.00
Basic Average Shares
3,743,332
--
670,355
642,990
639,190
Diluted Average Shares
3,743,332
--
670,355
684,076
676,658
Total Operating Income as Reported
-35,257
-35,257
-39,654
-12,245
4,031
Total Expenses
89,217
89,217
94,491
85,013
80,300
Net Income from Continuing & Discontinued Operation
-40,216
-40,216
-43,071
-13,776
2,886
Normalized Income
-39,286.75
-39,286.75
-39,223.50
-13,776
2,886
Interest Income
285
285
329
254
107
Interest Expense
4,107
4,107
2,441
669
491
Net Interest Income
-3,909
-3,909
-2,112
-412
-374
EBIT
-35,059
-35,059
-39,325
-11,988
4,148
EBITDA
-30,740
-30,740
-35,101
-7,822
8,280
Reconciled Cost of Revenue
25,462
25,462
26,342
23,262
22,106
Reconciled Depreciation
4,319
4,319
4,224
4,166
4,132
Net Income from Continuing Operation Net Minority Interest
-40,216
-40,216
-43,071
-13,776
2,886
Total Unusual Items Excluding Goodwill
-1,239
-1,239
-4,750
--
--
Total Unusual Items
-1,239
-1,239
-4,750
--
--
Normalized EBITDA
-29,501
-29,501
-30,351
-7,822
8,280
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-309.75
-309.75
-902.50
--
--
6/30/2021 - 10/11/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EVT.VI Evotec SE
8.50
-0.82%
 
TKUN.TA Tikun Olam-Cannbit Pharmaceuticals Ltd
38.00
-5.00%
 
PLCN.CN Cannibble Food-Tech Ltd.
0.0200
-33.33%
 
N4P.L N4 Pharma Plc
0.5750
0.00%
 
BOI.PA Boiron SA
25.20
+1.00%
 
TEV.F Teva Pharmaceutical Industries Limited
16.10
-2.13%
 
RJF.MC Laboratorio Reig Jofre, S.A.
2.6900
+1.13%
 
3320.HK China Resources Pharmaceutical Group Limited
5.480
+1.29%
 
DICOT.ST Dicot Pharma AB
0.2655
+1.53%
 
APH.L Alliance Pharma plc
60.80
+0.33%